Healthcare ETFs to Gain on Progress in COVID-19 Antibody Tests
Zacks Investment Research | Apr 16, 2020 04:40AM ET
The coronavirus pandemic has reached a grim mark, infecting more than 2.06 million. The death toll has risen to at least 137,000 globally, according to Johns Hopkins University. The number of confirmed cases in the United States have soared to at least 638,000, with more than 30,000 deaths. In this health crisis, global economies are under huge stress due to shutdown of economic activities and social distancing measures.
It is being believed that testing for COVID-19 is the major key in controlling the outbreak and making important decisions like treatment protocols, appropriate resource allocation and drafting the right healthcare policies. Along with molecular testing, antibody testing is gaining immense prominence as economies are struggling to reopen.
Amid these desperate times, Abbott Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.